Abraham Pinter, PhD, Rutgers University
A key focus of the work of Dr. Pinter's lab is understanding the basis for the inability of the immune system to control HIV, and identification of new targets and vaccine approaches that can overcome these limitations. The lab analyzes the role of conformational masking towards neutralization resistance, with a focus on specific determinants that contribute to masking and identification of mutations that can reverse this effect. Additionally, the lab focuses on the identification of antibodies in sera of HIV-infected subjects that possess broad and potent neutralizing activities. The information derived from the lab's studies is being used to design immunogens and vaccination strategies for inducing such broadly protective antibody responses.
Products
References
- Lostrom, ME , Stone, MR, Tam M, Burnette WN, Pinter A, Nowinski RC. Monoclonal antibodies against murine leukemia viruses: identification of six antigenic determinants on the p15(E) and gp70 envelope proteins. Virology 1979 Oct 30;98(2):336-50.
- Hammerling U., Pinter A, and O'donnell PV, (1980) Monoclonal Antibodies as a tool in research on oncogenic viruses. p. 255-256. In G. A. Gerth (ed). The role of viruses in human cancer (Elsevier, Amsterdam).
- Pinter, A., Honnen, WJ, Tung, JS, O'Donnell, PV. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology 1982 116(2):s 499-516
- Burkhart MD, Kayman SC, He Y, Pinter A. Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. J Virol. 2003 Apr;77(7):3993-4003.
